Recombinant Human Glypican 3 Protein


There are currently no images for Glypican 3 (2119-GP).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Binding Activity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human Glypican 3 Protein Summary

Details of Functionality
Measured by its binding ability in a functional ELISA. When Recombinant Human Glypican 3 is immobilized at 0.5 μg/mL (100 µL/well), the concentration of Recombinant Human FGF basic 146 aa (Catalog # 233-FB) that produces 50% of the optimal binding response is approximately 0.6-3 ng/mL.
Mouse myeloma cell line, NS0-derived human Glypican 3 protein
Met1-His559 with a C-terminal 6-His tag
Accession #
N-terminal Sequence
No results obtained: Gln25 predicted, Ser359 & Val483
Structure / Form
Glypican 3 is subject to endoproteolytic processing by proprotein convertases (PC). By amino acid sequencing, three peptides (the first with a blocked N-terminus most likely starts with Gln25, the second peptide starts with Ser359 after a furin cleavage site, and the third peptide starts with Val483) are present in the recombinant GPC3 preparation. Peptides 2 and 3 are detected at a 1:1 ratio. All three peptides remained associated via disulfide bonds.
Protein/Peptide Type
Recombinant Proteins
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


Theoretical MW
61.6 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
60-100 kDa, non-reducing conditions
Read Publications using
2119-GP in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Glypican 3 Protein

  • DGSX
  • Glypican 3
  • glypican proteoglycan 3
  • glypican-3
  • GPC3
  • GTR2-2
  • heparan sulphate proteoglycan
  • Intestinal protein OCI-5
  • MXR7
  • OCI5
  • OCI-5
  • secreted glypican-3
  • SGB
  • SGBS


Glypicans (GPC) are a family of heparan sulfate proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor. Six members of this family have been identified in mammals (GPC1-GPC6). All glypican core proteins contain an N-terminal signal peptide, a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C-terminal GPI attachment site. While glypican proteins do not share strong amino acid sequence identity (they range from 17-63%), the conserved cysteine residues in their CRDs suggests similarity in their
three‑dimensional structure (1, 2).

Mutations in GPC3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors (3). These features are also present in the mouse knock-out of GPC3 indicating that GPC3 regulates cell survival and inhibits cell proliferation during development (4). Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of GPC3 by proprotein convertases is required for the modulation of Wnt signaling (5). Direct interaction with FGF-basic has been observed and is mediated by the heparan sulfate chains (6).

  1. Filmus, J. and S.B. Selleck (2001) J. Clinical Invest. 108:497. 
  2. De Cat, B and G. David (2001) Seminars in Cell & Dev. Biol. 12:117. 
  3. Pilia, G. et al. (1996) Nat. Genet. 12: 241. 
  4. Cano-Gauci, D.F. et al. (1999) J. Cell Biol. 146: 255.
  5. De Cat, B. et al. (2003) J. Cell Biol. 163:625.
  6. Song, H.H. et al. (1997) J. Biol. Chem. 272:7574.

Customers Who Viewed This Item Also Viewed...

Species: Hu, Mu
Applications: WB, Simple Western, CyTOF-ready, ICC, ICFlow, KO
Species: Mu
Applications: WB, Flow, IHC, CyTOF-ready
Species: Hu
Applications: WB, IHC
Species: Hu, Rt
Applications: WB
Species: Hu, Mu, Rt
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP
Species: Hu
Applications: WB
Species: Hu, Mu, Rt, Po, Bv, Ca, Eq, Fe
Applications: WB, Simple Western, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu, Mu, Rb(-)
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-P, Flow-IC
Species: Hu
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Species: Hu, Mu, Rt, Pm, Pm
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu, Mu, Rt
Applications: WB, IHC, IHC-P
Species: Hu, Mu, Rt
Applications: WB, Simple Western, Flow, ICC/IF, IHC, IHC-P
Species: Hu, Mu
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu
Applications: WB, Simple Western, IHC
Species: Hu, Mu, Rt, Bv
Applications: WB, ICC/IF, IHC
Species: Hu, Mu, Po, Bv, Rb
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu
Applications: Binding Activity

Publications for Glypican 3 (2119-GP)(6)

We have publications tested in 3 confirmed species: Human, Mouse, N/A.

We have publications tested in 4 applications: Bioassay, ELISA (Standard), ELISA Development, In Vivo.

Filter By Application
ELISA (Standard)
ELISA Development
In Vivo
All Applications
Filter By Species
All Species
Showing Publications 1 - 6 of 6.
Publications using 2119-GP Applications Species
M Miura, N Fujinami, Y Shimizu, S Mizuno, K Saito, T Suzuki, M Konishi, S Takahashi, N Gotohda, K Suto, T Yoshida, T Nakatsura Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery Oncol Lett, 2020;19(4):2657-2666. 2020 [PMID: 32218816] (ELISA Development, Human) ELISA Development Human
T Ueda, A Kumagai, S Iriguchi, Y Yasui, T Miyasaka, K Nakagoshi, K Nakane, K Saito, M Takahashi, A Sasaki, S Yoshida, N Takasu, H Seno, Y Uemura, K Tamada, T Nakatsura, S Kaneko Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells Cancer Sci., 2020;111(5):1478-1490. 2020 [PMID: 32133731] (In Vivo, Mouse) In Vivo Mouse
Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate Sci Rep, 2016;6(0):26245. 2016 [PMID: 27185050] (ELISA (Standard), Human) ELISA (Standard) Human
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin. Cancer Res., 2012;18(13):3686-96. 2012 [PMID: 22577059] (ELISA (Standard), N/A) ELISA (Standard) N/A
Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin. Cancer Res., 2006;12(9):2689-97. 2006 [PMID: 16675560] (ELISA (Standard), N/A) ELISA (Standard) N/A
Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res., 2006;66(4):2414-22. 2006 [PMID: 16489048] (Bioassay, Mouse) Bioassay Mouse

Reviews for Glypican 3 (2119-GP) (0)

There are no reviews for Glypican 3 (2119-GP). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Glypican 3 (2119-GP) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Other Available Formats

Additional Glypican 3 Products

Bioinformatics Tool for Glypican 3 (2119-GP)

Discover related pathways, diseases and genes to Glypican 3 (2119-GP). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for Glypican 3 (2119-GP)

Discover more about diseases related to Glypican 3 (2119-GP).

Pathways for Glypican 3 (2119-GP)

View related products by pathway.

PTMs for Glypican 3 (2119-GP)

Learn more about PTMs related to Glypican 3 (2119-GP).

Blogs on Glypican 3.

Glypican 3 as a biomarker for gastro-esophageal adenocarcinoma
By Jamshed Arslan, Pharm. D., PhD. Gastroesophageal adenocarcinoma originates from the glandular epithelium of the esophagus, gastroesophageal junction and stomach. The incidence of gastroesophageal adenocarcinoma is...  Read full blog post.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human Glypican 3 Protein and receive a gift card or discount.


Gene Symbol GPC3